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Hormone replacement therapy as treatment of breast cancer- a phase II
study of Org OD 14 (tibilone)
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Summary Org OD 14 (tibilone) is a synthetic steroid, designed to combine the favourable effects of
oestrogens, progestagens and androgens into a single substance for use as hormone replacement therapy
(HRT). Given its antiovulatory properties, the ability to control menopausal symptoms and blocking action on
progesterone receptors, Org OD 14 was considered as an agent with potential anti-cancer activity while at the
same time helping existing menopausal symptoms. In this phase II study, 14 post-menopausal women with
advanced or metastatic breast cancer, who had failed on tamoxifen, were treated with Org OD 14. The median
duration of treatment was 12 weeks and all patients stopped because of progressive disease with or without
toxicity. Vaginal bleeding occurred in four patients, three of whom had recently stopped tamoxifen. One
response was seen: an 82-year-old patient had a partial response in an axillary soft tissue mass, improvement in
liver function tests and an improvement in her performance status that lasted over 6 months. One patient with
progressive disease on Org OD 14 improved on stopping the drug. In view of the vaginal bleeding, Org OD 14
should not be given to patients who have recently stopped tamoxifen.
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Treatment of advanced breast cancer is palliative, with
symptom control and quality of life being the main goals.
In this situation, tamoxifen is usually the first treatment of
choice and gave an overall response rate of 34% in a pooled
population of 5353 patients. The average duration of
remission was 18 months (Jackson et al., 1991). Second-line
hormone therapy gives response rates from 19% to 38% with
a variety of therapies (Wilson et al., 1983) and third-line
hormone therapy can benefit 42% of patients in terms of
disease stabilisation, symptom control or objective response
(Iveson et al., 1993).
Menopausal symptoms, including hot flushes, vaginal
dryness, loss of libido and mood changes are often induced
by chemotherapy given to pre- and post-menopausal women
with both early or advanced breast cancer (Sherwin and
Gelfand, 1985). These symptoms are all effectively controlled
by hormone replacement therapy (HRT), but this is usually
withheld from patients with breast cancer because of the fear
of stimulating or reactivating the cancer. This concern is
based on the increased risk of breast cancer in women with a
family history of breast cancer or in those with benign breast
cancer (Dupont and Page, 1991). Oestrogens have been used
in the treatment of breast cancer for many years. Initially
synthetic oestrogens, including diethylstilboestrol and ethiny-
loestradiol, were reported to give response rates of 30-40%
but with a high incidence of side-effects, the most common of
which were fluid retention and uterine bleeding (Stoll, 1964).
Premarin, a naturally occurring conjugated oestrogen, has
been used at a dose of 2.5 mg three times daily (i.e. 12 times
the dose used in HRT) in previously untreated patients with
metastatic breast cancer and gave a response rate of 45%
with a 24% incidence of uterine bleeding (Smith et al., 1979).
Org OD 14 (tibilone) is a synthetic steroid, designed to
combine the favourable effects of oestrogens, progestagens
and androgens into a single substance for use as HRT. It is
structurally related to 19-nortestosterone derivatives such as
norethisterone and norethynodrel. Following oral adminis-
tration of Org OD 14 to animals, oestrogenic, progestagenic
and weak androgenic activities have been demonstrated.
When compared with 19-nortestosterone and norethynodrel
in the rat, Org OD 14 had greater oestrogenic activity than
19-nortestosterone and equal to that of norethynodrel,
androgenic activity almost equal to 19-nortestosterone and
a weak progestational effect on the rabbit endometrium
compared with the other two compounds. Org OD 14
suppressed follicle-stimulatory hormone (FSH) and luteinis-
ing hormone (LH) in climacteric patients and inhibited
ovulation. In castrated male rats Org OD 14 could reduce
hypersecretion of pituitary gonadotrophins and prevent bone
loss following ovariectomy in rats. No mineralocorticoid or
glucocorticosteroid effects could be demonstrated (Tax,
1991).
Org OD 14 is metabolised to other steroid molecules,
namely the 4-ene isomer and the 3a- and 3,B-hydroxy
metabolites. Human myometrium was used in vitro as a
source of progesterone and oestrogen receptors and the 4-ene
isomer showed a marked binding to the progesterone
receptors, explaining the weak proliferative effect of this
drug on the endometrium in vivo.
In a placebo-controlled study in post-menopausal women,
no net bone loss was noted in the patients receiving Org OD
14, but patients receiving placebo continued to lose bone at
the predicted rate (Lindsay et al., 1978). Org OD 14 has been
shown to be effective in the treatment of menopausal
symptoms in a double-blind multicentre cross-over study vs
placebo (Tax et al., 1987; Trevoux et al., 1983). Given its
antiovulatory properties, the ability to control menopausal
symptoms and blocking action on progesterone receptors,
Org OD 14 was considered as an agent with potential anti-
cancer activity while at the same time helping existing
menopausal symptoms.
This was a phase II study of the use of Org OD 14 in
women with breast cancer who had failed tamoxifen therapy.
Patients and methods
Patients
Post-menopausal patients with histologically proven breast
carcinoma who had locally advanced or metastatic disease, in
whom further endocrine therapy was considered a suitable
treatment option, as they had previously received tamoxifen,
were entered into this study. Patients of any age with a life
expectancy of at least 3 months and a WHO performance
status of <2 were considered eligible. A period of 4 weeks
was necessary between stopping tamoxifen and commencing
tibilone and all patients had clinically or radiologically
assessable disease. Patients were excluded if their disease
was rapidly progressing or if they had life-threatening
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November 1995metastases, i.e. central nervous system disease, lymphangitis
carcinomatosis, liver metastases with abnormal liver function
tests and extensive bone disease or hypercalcaemia. Other
exclusion criteria were significant renal dysfunction, epilepsy
or hormone-related migraine, a past history of thromboem-
bolic disease a second primary cancer, except in situ
carcinoma of the cervix or basal skin cancer. All patients
gave witnessed, informed consent according to the guidelines
of the Royal Marsden Hospital Ethics Committee.
Investigations
Before treatment patients were clinically assessed and blood
counts, serum urea, creatinine, electrolytes, calcium, liver
function tests, chest radiograph, limited skeletal survey and
bone scan were carried out. Liver ultrasound was performed
if clinically indicated. The presence of menopausal symptoms
was assessed by direct questioning of the patients - hot
flushes, night sweats, mood changes, insomnia, vaginal
dryness and loss of libido were documented. A calcium
level was measured on day 7. Patients were seen at 6 weeks
and assessed for disease status at 3 months.
Treatment
Org OD 14 (Livial) 2.5 mg was given once per day during an
initial treatment period of 3 months.
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Table I Patient characteristics
Median age (years)
Median performance status
Previous treatment
Adjuvant chemotherapy
Adjuvant endocrine
Chemotherapy (metastatic)
Endocrine (recurrent)
Previous endocrine therapies
One
Two
Three
Sites of disease
Bone
Lung/pleura
Locoregional
Skin
Liver
Mediastinum
Oestrogen receptor status
Positive
Negative
Not known
Years since menopause
Natural >3 years
Hysterectomy >3 years
Oophorectomy >3 years
LHRH agonist 2 years ago
63 (range 43-83)
1 (range 0-2)
3
5
11
9
3
2
13
4
3
3
2
1
2
3
9
10
2
1
1
Criteria for response and toxicity
Patients who had received a minimum of 6 weeks of
treatment or who showed evidence of progressive disease
after 2 weeks were considered assessable for response using
standard International Union Against Cancer (UICC) criteria
(Hayward et al., 1977). Objective assessment of response was
performed at 3 months by clinical examination and repetition
ofprestudy investigations. The response duration was defined
as the time elapsed between the start of treatment with Org
OD 14 and the date of progressive disease or last follow-up.
Toxicity was assessed according to WHO criteria.
Statistical analysis
Statistical evaluation of the response rate was performed
using the Poisson distribution for calculating 95% confidence
intervals. Fourteen assessable patients were necessary, in
which one response was needed before further patients would
be recruited.
Results
Patient characteristics
Fourteen patients were entered into the study (Table I). The
median age of the 14 post-menopausal patients was 63 years
(range 43-83 years). Six patients had received chemotherapy
(one adjuvant) in addition to hormone therapy. All patients
had assessable disease: six patients had metastatic disease in
only one site, four patients had disease in two sites and four
patients had disease at three sites. The sites of disease were
bone in 13 patients, liver in two patients, locoregional disease
in three patients, lung in four patients, skin in three patients
and mediastinum in one patient.
Toxicity and compliance
Compliance was good in all patients. The median duration of
treatment was 12 weeks (range 3-24 weeks). All patients
stopped because of progressive disease with or without
toxicity. Vaginal bleeding was the main toxicity and
occurred in four patients: one patient had spotting, one had
12 weeks' continuous light spotting and one had a heavy
withdrawal bleed with flooding, requiring her to be seen at
the local casualty department. One patient with progressive
disease asked to stop because of heavy menstruation-like
vaginal bleeding. One patient had grade 1 nausea and
stopped treatment for a week but was then able to start it
again without a return of the nausea. Another patient
required an additional oral hypoglycaemic agent for control
of her diabetes and at the time developed a grade 1 infection
in the form of a unilateral parotitis that required antibiotics.
Depression was reported in a patient during the 12 weeks of
treatment, which disappeared on stopping Org OD 14.
Symptoms control
All patients except one were at least 2 years out from the
menopause and 13/14 were 3 years out. Only one patient had
menopausal symptoms before taking tibilone and this patient
reported improvement in her hot flushes.
Responses
One responder was seen in this study. The patient had an
axillary soft tissue mass that partially responded, and in
addition, her liver function tests improved and she had an
improvement in performance status. The response lasted 24
weeks from the beginning of treatment.
Oestrogen receptor (ER) status
The ER status was unknown in 9/14 patients, three were ER
negative and two were positive (74 and 21 fmol-'). This last
patient achieved an objective response.
Subsequent treatment
One patient who progressed on Org OD 14 had a withdrawal
response after stopping it, with a disappearance of hip pain
that had developed on Org OD 14 and a stabilisation of her
skin infiltration that had been previously progressing on Org
OD 14. Four patients went on to receive chemotherapy and
five received further endocrine therapy with an aromatase
inhibitor. Of the patients on chemotherapy, three out of four
achieved a partial response and three out offive responded to
further hormonotherapy.MTin breast catiwe
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In this study of 14 patients with metastatic breast cancer, one
response was observed. The patient who responded was 82
years old, with an ER-positive tumour. She showed a
biochemical improvement in her liver function tests and an
objective decrease in the size of the soft tissue disease in the
axilla; in addition her performance status improved from 2 to
1. We did not continue to recruit after 14 patients as we felt
that the toxicity seen, i.e. the vaginal bleeding, was excessive
and defeated the initial purpose of this study. In retrospect,
patients probably need longer than 4 weeks between stopping
tamoxifen and starting tibilone. Although we did see one
objective response there was one patient in whom tibilone
may have contributed to disease progression. The multi-
functional nature of the Org OD 14 molecule contributed to
the effect on diabetic control observed in one of our patients
and made this compound unsuitable for further study.
The use of HRT in patients with breast cancer in
situations in which patients have severe uncontrolled
menopausal symptoms that are affecting their quality of life
is a difficult decision (Powles et al., 1993) and therefore its
role does need to be assessed in randomised trials. An agent
with anti-breast cancer activity but without the side-effects of
menopausal symptoms is not impossible as Org OD 14 has
shown such activity, but the toxicity profile found in this
protocol precluded further testing.
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